A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Phase 2 Completed 300 enrolled Aldeyra Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects with Dry Eye Disease

Timeline

Start: 2018-01-02
Primary completion: 2018-07-11
Completion: 2018-07-11

Publications

Results Clark D, Sheppard J, Brady TC. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease. J Ocul Pharmacol Ther. 2021 May;37(4):193-199. doi: 10.1089/jop.2020.0087. Epub 2021 Jan 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Reproxalap	Other / unclassified	0.1 %	Topical
Subject	Reproxalap	Other / unclassified	0.25 %	Topical

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Summary

Timeline

Publications

Drugs

Indications